

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27129/33783B	Serial No. 09/994,185
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		Applicant White <i>et al.</i>	
		Filing Date November 26, 2001	Group TBD

## U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
KAC	A1	5,484,705	01/16/96	White			
KAC	A2	5,245,013	09/14/93	Ulevitch			
KAC	A3	5,310,879	05/10/94	Ulevitch			

## FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
KAC	B1	WO 91/01639	02/21/91	PCT				
	B2	WO 93/06228	04/01/93	PCT				
	B3	WO 94/21280	09/29/94	PCT				
	B4	WO 94/25476	11/10/94	PCT				
	B5	WO 95/00641	01/05/95	PCT				
	B6	WO 95/02414	01/26/95	PCT				

EXAMINER <i>Karen A. Camille</i>	DATE CONSIDERED 11/2/2004
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27129/33783B	Serial No. 09/994,185
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		Applicant White <i>et al.</i>	
		Filing Date November 26, 2001	Group TBD

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

KAI	C1	Dofferhoff <i>et al.</i> , "Tumor necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature", <i>Netherlands J. Med.</i> , 39:45-62 (1991).
	C2	Elsbach <i>et al.</i> , "Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a Closely Associated Phospholipase A <sub>2</sub> from Rabbit Polymorphonuclear Leukocytes", <i>J. Biol. Chem.</i> , 254(21):11000-11009 (November 10, 1979).
	C3	Erwin and Munford, "Plasma Lipopolysaccharide-Deacylating Activity (Acyloxyacyl Hydrolase) Increases After Lipopolysaccharide Administration to Rabbits", <i>Lab. Invest.</i> , 65(2):138-144 (1991).
	C4	Gallay <i>et al.</i> , "Purification and Characterization of Murine Lipopolysaccharide-Binding Protein", <i>Infect. Immun.</i> 61(2):378-383 (February 1993).
	C5	Gazzano-Santoro <i>et al.</i> , "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide", <i>Infect. Immun.</i> 60(11):4754-4761 (November 1992).
	C6	Leturcq <i>et al.</i> , "Generation of Monoclonal Antibodies to Human LBP and Their Use in the Detection of LBP Protein in Serum", <i>J. Cell. Biochem.</i> , 16C:161 (1992).
	C7	Marra <i>et al.</i> , "The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin", <i>J. Immun.</i> , 148(2):532-537 (January 15, 1992).
	C8	Pereira <i>et al.</i> , "Quantitation of a cationic antimicrobial granule protein of human polymorphonuclear leukocytes by ELISA", <i>J. Immunol. Methods</i> , 117:115-120 (1989).
	C9	Pesce <i>et al.</i> , "Cationic antigens Problems associated with measurement by ELISA", <i>J. Immunol. Methods</i> , 87:21-27 (1986).
	C10	Schindler <i>et al.</i> , "Plasma levels of bactericidal/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP) during hemodialysis", <i>Clin. Nephrology</i> , 40(6):346-351 (1993).

EXAMINER: <i>Karm A. Gammella</i>	DATE CONSIDERED: <i>11/2/2004</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 27129/33783B	Serial No. 09/994,185
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		Applicant White <i>et al.</i>	
		Filing Date November 26, 2001	Group TBD

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

KAC	C11	Schumann <i>et al.</i> , "Structure and Function of Lipopolysaccharide Binding Protein", <i>Science</i> , 249:1429-1433 (September 21, 1990).
	C12	Spitznagel, "Antibiotic Proteins of Human Neutrophilia", <i>J. Clin. Invest.</i> , 86:1381-1386 (1990).
	C13	Taber <i>et al.</i> , Taber's Cyclopedic Medical Dictionary, pp 545 (F.A. Davis Co., Philadelphia) (1985).
	C14	Ulevitch, Presentation at the American Society of Microbiology General Meeting in Atlanta, Georgia (May 16-21, 1993).
	C15	von der Mohien <i>et al.</i> , Bactericidal/Permeability-Increasing Protein Levels Predict Survival in Patients with Gram-Negative Sepsis", Abstract presented at 13th International Symposium on Intensive Care and Emergency Medicine, (Brussels, Belgium) (March 1993).
	C16	Weiss and Olsson, "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils", <i>Blood</i> , 69(2):652-659 (February 1987).
	C17	Weiss <i>et al.</i> , "Human Bactericidal/Permeability-Increasing Protein and a Recombinant NH <sub>2</sub> - Terminal Fragment Cause Killing of Serum-resistant Gram-negative Bacteria in Whole Blood and Inhibit Tumor Necrosis Factor Release Induced by the Bacteria", <i>J. Clin. Invest.</i> 90:1122-1130 (September 1992).
	C18	Weiss <i>et al.</i> , "Purification and Characterization of a Potent Bactericidal and Membrane Active Protein from the Granules of Human Polymorphonuclear Leukocytes", <i>J. Biol. Chem.</i> , 253(8):2664-2672 (April 25, 1978).
	C19	White <i>et al.</i> , "Measurement of bactericidal/permeability-increasing protein in human body fluids by sandwich ELISA", <i>J. Immunol. Methods</i> , 167:227-235 (1994).
	C20	Wright <i>et al.</i> , "CD14, a Receptor for Complexes of Lipopolysaccharide (LPS) and LPS Binding Protein", <i>Science</i> , 249:1431-1433 (September 21, 1990).
✓	C21	Ulevitch, Presentation at the American Society of Microbiology General Meeting in Atlanta, Georgia (May 16-21, 1993) (Session 13 Abstract 564).

EXAMINER <i>Karen G. Canella</i>	DATE CONSIDERED <i>11/2/2004</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
27129/33783BSerial No.  
09/994,185Applicant  
White *et al.*Filing Date  
November 26, 2001Group  
TBD

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

KAL	C22	Tobias et al., "Lipopolysaccharide Binding Protein" <i>J. Cell. Biochem.</i> , 16 C:151 (Abstract (CB006) (1992)
	C23	Ballou et al., "Laboratory Evaluation of Inflammation," <i>Textbook of Rheumatology</i> , Vol. 1, Ch. 40, pp. 671-679 (1993)
	C24	Baumann et al., "The acute phase response," <i>Immunology Today</i> , Vol. 15, 1/2, 2, pp. 74-80 (1994)
	C25	Grube et al., "Lipopolysaccharide Binding Protein Expression in Primary Human Hepatocytes and HepG2 Hepatoma Cells*," <i>J. Biol. Chem.</i> , Vol. 269, No. 11, pp. 8477-8482 (1994)
	C26	Raynes, "Carbohydrate Binding Proteins and Immune Responses," Biochemical Immunology Group/Glycobiology Group Joint Colloquium Organized by G.B. Wisdom and M.I. Halliday (The Queen's University, Belfast) and Edited by G.B. Wisdom. 648th Meeting held at the Queen's University, Belfast, 14-17 September 1993, <i>Biochemical Society Transactions</i> , Vol. 22, pp. 69-74 (1994)
	C27	Meszáros et al., "Immunoreactivity and Bioactivity of Lipopolysaccharide-Binding Protein in Normal and Heat-Inactivated Sera," <i>Infection and Immunity</i> , Vol. 63, No. 1, pp. 363-366 (1995)
	C28	Pugin et al., "Soluble CD14 and Lipopolysaccharide Binding Protein Mediate Epithelial Cell Responses to Lipopolysaccharides," <i>FASEB J.</i> , A142 (1993)
	C29	Geller et al., <i>Arch. Surg.</i> , 128:22-28 (1993)
	C30	Tobias, <i>J. Biol. Chem.</i> , 263:13479-13481 (1988)
	C31	Schumann, <i>Science</i> , 249:1429-1431 (1990)
	C32	Dubin et al., "Asthma and Endotoxin: Lipopolysaccharide-Binding Protein and Soluble CD14 in Bronchoalveolar Compartment," <i>Am. J. Physiol.</i> , 270:L736-L744 (1996)
✓	C33	Froon et al., "Lipopolysaccharide Toxicity -- Regulating Proteins in Bacteremia," <i>J. Infect. Dis.</i> , 171:1250-1257 (1995)

EXAMINER

Karen A. Gault

DATE CONSIDERED

11/21/2009

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Any. Docket No. 27129/33783B	Serial No. 09/994,185
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		Applicant White <i>et al.</i>	
		Filing Date November 26, 2001	Group TBD

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

KAC	C34	Heumann et al., "Radioimmunoassay versus flow cytometric assay to quantify LPS-binding protein (LBP) concentrations in human plasma," <i>J. Immunol. Meth.</i> , 171:169-176 (1994)
	C35	Iriye et al., "Differences in the Concentration of an Endotoxin Binding Protein Help Explain Sensitivity to Septic Complications in Pregnancy," <i>Am. J. Obstetrics Gynecol.</i> , 174(1 pt. 2):390 (1996)
	C36	Nakayama et al., "Monitoring Both Serum Amyloid Protein A and C-Reactive Proteins as Inflammatory Markers in Infectious Diseases," <i>Clin. Chem.</i> 39:293-297 (1993)
✓	C37	Schumann et al., 36th Int'l Conf. on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15-18, (1996)

EXAMINER <i>Karen A. Gannell</i>	DATE CONSIDERED <i>11/2/2004</i>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	